Expleo Solutions Intrinsic Value
EXPLEOSOL • Information Technology
Current Stock Price
₹720.85
Primary Intrinsic Value
₹1229.76
Market Cap
₹1153 Cr
+17.1%
Upside
Median Value
₹844.44
Value Range
₹398 - ₹1520
Assessment
Trading Below Median Value
Safety Margin
14.6%
EXPLEOSOL Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1229.76 | ₹983.81 - ₹1475.71 | +70.6% | EPS: ₹102.48, Sector P/E: 12x |
| Book Value Method | asset | ₹397.50 | ₹357.75 - ₹437.25 | -44.9% | Book Value/Share: ₹397.50, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹590.00 | ₹531.00 - ₹649.00 | -18.2% | Revenue/Share: ₹737.50, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹885.00 | ₹796.50 - ₹973.50 | +22.8% | EBITDA: ₹236.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹1519.64 | ₹1215.71 - ₹1823.57 | +110.8% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹655.87 | ₹590.28 - ₹721.46 | -9.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹844.44 | ₹760.00 - ₹928.88 | +17.1% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹1441.70 | ₹1297.53 - ₹1585.87 | +100.0% | ROE: 25.2%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹795.00 | ₹715.50 - ₹874.50 | +10.3% | EPS: ₹102.48, BVPS: ₹397.50 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
EXPLEOSOL Intrinsic Value Analysis
What is the intrinsic value of EXPLEOSOL?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Expleo Solutions (EXPLEOSOL) is ₹844.44 (median value). With the current market price of ₹720.85, this represents a +17.1% variance from our estimated fair value.
The valuation range spans from ₹397.50 to ₹1519.64, indicating ₹397.50 - ₹1519.64.
Is EXPLEOSOL undervalued or overvalued?
Based on our multi-method analysis, Expleo Solutions (EXPLEOSOL) appears to be trading below median value by approximately 17.1%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 11.04 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 25.2% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 17.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.42x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Expleo Solutions
Additional stock information and data for EXPLEOSOL
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹179 Cr | ₹154 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹71 Cr | ₹55 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹23 Cr | ₹5 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹24 Cr | ₹24 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹66 Cr | ₹44 Cr | Positive Free Cash Flow | 8/10 |